<SEC-DOCUMENT>0001104659-20-132213.txt : 20201204
<SEC-HEADER>0001104659-20-132213.hdr.sgml : 20201204
<ACCEPTANCE-DATETIME>20201204070420
ACCESSION NUMBER:		0001104659-20-132213
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201204
FILED AS OF DATE:		20201204
DATE AS OF CHANGE:		20201204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		201368708

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2037569d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of December 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM 40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On December 4, 2020, CureVac N.V. (the
 &ldquo;Company&rdquo;) issued a press release announcing the appointment of Antony Blanc as Chief Business Officer and Chief Commercial
Officer of the Company. The press release is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The information
in this Form 6-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: top; width: 28%"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 20%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 4, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 0.9in; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="padding-top: 3pt; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-top: 3pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; vertical-align: top"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated December 4, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2037569d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>CureVac Appoints
Antony Blanc as Chief Business Officer and Chief Commercial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>T&Uuml;BINGEN,
Germany/ BOSTON, USA &ndash; December 4, 2020</B></FONT> &ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CureVac
N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines
based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), announced today that Antony Blanc, PhD, has been appointed Chief
Business Officer and Chief Commercial Officer of CureVac. In this role, he will be responsible for building the network of
partnerships that will support the growth of CureVac, for developing the competitiveness and commercial relevance of the
company&acute;s programs in development and for building the commercial organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;We
welcome Antony with his expertise and believe that he will be a great asset to the company,&rdquo; said Jean
St&eacute;phenne, Chairman of the Supervisory Board of CureVac. &ldquo;He combines expertise in science and business with
specific knowledge in RNA research. This will further support the company&rsquo;s efforts to develop mRNA-based
medicines.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&ldquo;It is
great timing that Antony is joining the executive board of CureVac now,&rdquo; said Dr. Franz-Werner Haas, CEO of CureVac.
 &ldquo;Antony will be an additional highly experienced team member and can further support our corporate business development
agenda and growth of the company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Antony Blanc
previously served biotech clients in Europe as an Associate Partner with McKinsey &amp; Company. Between 2009 and 2017, he
developed deep and broad cross-functional expertise in vaccines by serving in several senior roles at GSK Vaccines, including
leading strategic marketing, strategic pricing, joint ventures and the integration of the Novartis Vaccines business unit.
From 2000 to 2009, Blanc held leadership roles at several biotech companies, such as Chief Business Officer  at Synosia and
Head of Biopharma at Syngenta. He started his career at the strategy consulting firm McKinsey &amp; Company in 1994, focusing
on pharma and biotech.  He holds a Ph.D. in Molecular Biology and a BS.c. in Biochemistry from McGill University in Montreal,
Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Antony is pleased
to join CureVac and to work on mRNA, as mRNA was always special to him: &ldquo;My Ph.D. thesis was about translational control of
mRNA, and it is a wonderful twist of events that after all the experience I have been able to gather in consulting, biotech and
vaccines, I am returning to mRNA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 5pt"><B>About
CVnCoV&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">CureVac
began development of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimized, non-chemically modified
mRNA, encoding the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. Phase 1 and 2a clinical trials of
CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally
well tolerated across all tested doses and induced strong antibody responses in addition to first indication of T cell activation.
The quality of immune response was comparable to recovered COVID-19 patients, mimicking the immune response after natural COVID-19
infection. The data support CureVac&rsquo;s decision to advance a 12&micro;g dose in its upcoming pivotal Phase 2b/3 study, which
CureVac plans to initiate before the end of 2020. Clinical trial material is provided by the company&rsquo;s substantial production
capacities for mRNA vaccines at its headquarters in T&uuml;bingen, supported by the current expansion of manufacturing capacities
to allow for broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 5pt"><B>About
CureVac</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">CureVac
is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in
developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology
is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of
fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across
the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its
initial public offering on the New York Nasdaq in August 2020. It is headquartered in T&uuml;bingen, Germany, and employs more
than 500 people at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 5pt"><B>CureVac
Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Thorsten
Sch&uuml;ller, Vice President Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">CureVac,
T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">T:
+49 7071 9883-1577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">thorsten.schueller@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 5pt"><B>CureVac
Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Dr.
Sarah Fakih, Vice President Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">CureVac,
T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">T:
+49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">M:
+49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">sarah.fakih@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 5pt"><B>Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B></B><FONT STYLE="font-size: 10pt">This press release contains statements that constitute &ldquo;forward looking statements&rdquo;
as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express
the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the &ldquo;company&rdquo;) regarding
future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the
company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking
statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project<STRIKE>,</STRIKE>&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative
of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s
performance, and you should not place undue reliance on such statements.&nbsp; Forward-looking statements are subject to many
risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability
and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical
studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration
partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation,
regulations and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry,
the effects of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance
on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating
results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate
and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements
included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines,
any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect
future events or developments, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">For further information,
please reference the company&rsquo;s reports and documents filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC).
You may get these documents by visiting EDGAR on the&nbsp;SEC&nbsp;website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U )8# 2(  A$! Q$!_\0
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M#GJ?3TZC\,$9Z8R/'/BQ^T+\%O@;8?VE\5OB-X:\&1M#+<6]GJ%S+<ZY>QQ
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MPM)PE&MCH+]Y+]WPGA/P[PIP_D?%GC+Q/C^&Z'$V AG'#' 7"V7X;-?$'/\
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M%.EZ0TOE3RW-S%J%C'JL*WL%O<.9(98+;^@1QL#L3@;1DDG.XDY)'0?*3D8
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M4_E_>&>K!NGM@Y)X)SD^HX]J_%.7X[?\%(D\$>//C5H&A)\0OACXW^%WP?\
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A'WBWQAJVE7DPLY(;/7(],6SB@TZ%Y?HZBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
